Phase I/II dose-escalation trial of RGX-111 for the treatment of mucopolysaccharidosis type I

Trial Profile

Phase I/II dose-escalation trial of RGX-111 for the treatment of mucopolysaccharidosis type I

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs RGX 111 (Primary)
  • Indications Mucopolysaccharidosis I
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 06 Jan 2017 According to a REGENXBIO media release, the company expects to begin enrollment in the study in the second half of 2017.
    • 05 Jul 2016 According to Regenxbio media release, company expects to submit an IND of RGX-111 in the U.S. and Canada in the first half of 2017.
    • 07 Jan 2016 According to a media release, REGENXBIO intends to file IND application with the FDA in the first half of 2016 and plans to initiate this trial in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top